Key terms

About ALLO

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ALLO news

Apr 15 8:42am ET IO Biotech appoints Shamsaei as SVP, Commercial Development by TipRanks Mar 20 4:55am ET Allogene Therapeutics management to meet with Truist by TipRanks Mar 19 10:05pm ET Stifel Nicolaus Sticks to Their Hold Rating for Allogene Therapeutics (ALLO) by TipRanks Mar 19 8:11am ET Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE) by TipRanks Mar 19 6:27am ET Allogene Therapeutics: A Buy Rating on Strong Financials and Promising Clinical Prospects by TipRanks Mar 19 4:55am ET Allogene Therapeutics management to meet with Truist by TipRanks Mar 19 1:46am ET Allogene Therapeutics Poised for Growth: A Strong Buy Rating Amidst Innovative Trials and Strategic Advancements by TipRanks Mar 18 4:22pm ET Allogene Therapeutics management to meet with Truist by TipRanks Mar 16 2:01am ET Allogene Therapeutics’ Stability Threatened by Banking Sector Turmoil by TipRanks Mar 15 12:03pm ET JPMorgan biotech/pharma analysts hold an analyst/industry conference call by TipRanks Mar 14 5:22pm ET Allogene Therapeutics files $500M mixed securities shelf by TipRanks Mar 14 4:29pm ET Allogene Therapeutics sees $190M reduction in cash in 2024 by TipRanks Mar 14 4:28pm ET Allogene Therapeutics reports Q4 EPS (51c), consensus (45c) by TipRanks Mar 12 12:50pm ET Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Pliant Therapeutics (PLRX) by TipRanks Mar 12 8:41am ET Allogene, Arbor enter global gene editing license agreement by TipRanks Mar 07 4:55am ET Allogene Therapeutics management to meet with Truist by TipRanks Mar 06 5:55am ET Allogene Therapeutics management to meet with Truist by TipRanks Mar 04 10:24am ET Allogene Therapeutics management to meet with Truist by TipRanks Feb 16 8:35am ET Allogene Therapeutics to restate previously filed financial statements by TipRanks Feb 15 1:23am ET Allogene Therapeutics: A Strong Buy on Promising ALPHA3 Study and Potential Clinical Success by TipRanks Jan 19 6:20am ET Allogene Therapeutics price target lowered to $10 from $12 at H.C. Wainwright by TipRanks

No recent press releases are available for ALLO

ALLO Financials

1-year income & revenue

Key terms

ALLO Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ALLO Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

People walk past the New York Stock Exchange (NYSE) on March 28, 2024 in New York City.
NDZ/STAR MAX/IPx/AP
What stalled this year’s seemingly infallible stock market rally
A working oil pumpjack is pictured in Taft, Kern County, California on September 21, 2023.
Frederic J. Brown/AFP/Getty Images
Oil prices get short-lived boost from attack on Iran
NEW YORK, NEW YORK - FEBRUARY 08: A New York Community Bank stands in Brooklyn on February 08, 2024 in New York City. New York Community Bancorp, a regional lender, shed about 60% of its value over the past eight days and its credit rating has been downgraded to Junk by Moody's. (Photo by Spencer Platt/Getty Images)
Spencer Platt/Getty Images
US regional banks are still under pressure. That’s likely to continue
Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days